MARKET

COLL

COLL

Collegium Pharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

23.41
-0.51
-2.13%
Closed 17:10 01/17 EST
OPEN
23.92
PREV CLOSE
23.92
HIGH
24.40
LOW
23.39
VOLUME
232.14K
TURNOVER
--
52 WEEK HIGH
24.72
52 WEEK LOW
10.01
MARKET CAP
784.87M
P/E (TTM)
-69.0764
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of COLL and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

COLL News

  • The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares
  • Benzinga.3d ago
  • The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics
  • Benzinga.4d ago
  • Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now?
  • Zacks.6d ago
  • The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug
  • Benzinga.6d ago

More

Industry

Pharmaceuticals
+0.13%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About COLL

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting. Xtampza ER is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
More

Webull offers Collegium Pharmaceutical Inc (COLL) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.